PAP
ELVN icon

Persistent Asset Partners’s Enliven Therapeutics ELVN Stock Holding History

Persistent Asset Partners’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$479K Buy
9,433
+2,827
+43% +$120K 0.14% 117
2026
Q1 		$259K Buy
+6,606
New +$183K 0.1% 167

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Persistent Asset Partners's ELVN Position: Q2 2026 in Review

Persistent Asset Partners increased its Enliven Therapeutics (ELVN) stake by 43% in Q2 2026, buying an estimated $120K and bringing the position to 9,433 shares worth $479K. The position accounts for 0.14% of the portfolio, ranked #117.

Persistent Asset Partners first reported a position in ELVN in Q1 2026 and has held it in 2 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Persistent Asset Partners held 9,433 shares of Enliven Therapeutics worth $479K as of Q2 2026.
  • Persistent Asset Partners bought 2,827 Enliven Therapeutics shares in Q2 2026, an estimated $120K.
  • Enliven Therapeutics made up 0.14% of Persistent Asset Partners's portfolio in Q2 2026, its #117 holding.
  • Persistent Asset Partners first reported a position in Enliven Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.